Interval duration of roselixizumab treatment for myasthenia gravis

Rozanolixizumab (Rozanolixizumab), as an innovative FcRn inhibitor, mainly reduces the level of pathogenic autoantibodies in the serum by blocking the IgG recycling pathway for the production of new antibodies, thereby achieving the purpose of treating myasthenia gravis (MG; rare disease ). The treatment plan is designed to stratify the dose around the patient's weight, and is injected subcutaneously once a week for 6 consecutive weeks to form a complete course of treatment. The design of this 6-week cycle is based on the pharmacokinetic characteristics and clinical efficacy observation of the drug, ensuring that while effectively reducing pathological antibodies, potential adverse reactions are minimized.

There is currently no fixed and unified international standard for the selection of treatment interval. The main reason is thatMG’s condition fluctuates greatly and patients have individual differences in drug response. Under normal circumstances, after the first course of treatment, the doctor will make a comprehensive judgment on whether the treatment needs to be continued or the interval should be extended based on the patient's muscle strength recovery, autoantibody level monitoring, and adverse reaction manifestations. Some patients may experience significant improvement in symptoms and stable muscle strength after the first 6-week course of treatment. At this time, the interval between the next course of treatment can be appropriately extended, such as several weeks to several months, to reduce the burden of medication and reduce the risk of immunosuppression.

On the other hand, myasthenia gravis is characterized by recurrence and fluctuation, and some patients may experience worsening or recurrence of symptoms during the interval between treatments. If clinical symptoms and objective examination indicators show that the condition is worsening, it is necessary to consider starting the next treatment cycle as soon as possible and shorten the treatment interval. Existing research and clinical practice recommend that you avoid starting a new course of treatment within 63 days of the first course of treatment, mainly for safety reasons and to prevent the risk of infection and other side effects caused by excessive immunosuppression.

Additionally, the speed of injection and mode of administration of the drug are as important to maintaining efficacy as patient tolerability. Rozelixizumab is injected slowly subcutaneously using an infusion pump, with a maximum speed of 20 ml per hour, which helps reduce the incidence of local discomfort and systemic reactions.

Reference materials:https://www.drugs.com/rystiggo.html